Angiogenic Factor AGGF1 Promotes Therapeutic Angiogenesis in a Mouse Limb Ischemia Model

Qiulun Lu1, Yihong Yao1, Yufeng Yao1, Shizhi Liu1, Yuan Huang1, Shan Lu1, Ying Bai1, Bisheng Zhou1, Yan Xu1, Lei Li1, Nan Wang1, Li Wang1, Jie Zhang1, Xiang Cheng2, Gangjian Qin3, Wei Ma4, Chengqi Xu1, Xin Tu1*, Qing Wang1**

1 Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Center for Human Genome Research, Cardio-X Institute, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, 2 Institute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, 3 Feinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America, 4 The First Hospital of Wuhan City, Wuhan, People’s Republic of China, 5 Center for Cardiovascular Genetics, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America

Abstract

Background: Peripheral arterial disease (PAD) is a common disease accounting for about 12% of the adult population, and causes significant morbidity and mortality. Therapeutic angiogenesis using angiogenic factors has been considered to be a potential treatment option for PAD patients. In this study, we assessed the potential of a new angiogenic factor AGGF1 for therapeutic angiogenesis in a critical limb ischemia model in mice for PAD.

Methods and Results: We generated a unilateral hindlimb ischemia model in mice by ligation of the right common iliac artery and femoral artery. Ischemic mice with intramuscular administration of DNA for an expression plasmid for human AGGF1 (AGGF1 group) resulted in increased expression of both AGGF1 mRNA and protein after the administration compared with control mice with injection of the empty vector (control group). Color PW Doppler echocardiography showed that the blood flow in ischemic hindlimbs was significantly increased in the AGGF1 group compared to control mice at time points of 7, 14, and 28 days after DNA administration (n = 9/group, P = 0.049, 0.001, and 0.001, respectively). Increased blood flow in the AGGF1 group was correlated to increased density of CD31-positive vessels and decreased necrosis in muscle tissues injected with AGGF1 DNA compared with the control tissue injected with the empty vector. Ambulatory impairment was significantly reduced in the AGGF1 group compared to the control group (P = 0.004). The effect of AGGF1 was dose-dependent. At day 28 after gene transfer, AGGF1 was significantly better in increasing blood flow than FGF-2 (P = 0.034), although no difference was found for tissue necrosis and ambulatory impairment.

Conclusions: These data establish AGGF1 as a candidate therapeutic agent for therapeutic angiogenesis to treat PAD.

Introduction

Peripheral arterial disease (PAD) is caused by atherosclerosis, which results in progressive narrowing and occlusion of the peripheral arteries and inhibits blood flow to the lower extremities [1,2]. The prevalence of PAD is increasing in the modern aging society, and reaches about 12% of the adult population [3,4]. In the US, approximately 8 to 12 million people are affected with PAD [5]. In Germany, the prevalence of PAD for women and men aged ≥65 years was 17% and 20%, respectively [6].

The clinical presentation of PAD may vary from being asymptomatic to presenting with a serious symptom of intermittent claudication [1,7]. In severe cases, PAD significantly affects quality of life, and increases morbidity and mortality. Approximately 25% patients with critical limb ischemia die in one year [8]. Moreover, in patients with PAD the prevalence of coronary artery disease (CAD) is about 46% to 71% [9,10], and at least 10% of them suffered cerebrovascular disease [1,2,11,12].

The current treatment for PAD focuses on decreasing cardiovascular and cerebrovascular morbidity and mortality and on relieving PAD symptoms [13]. Pharmacological treatments with lipid-lowering, antihypertensive, and antithrombotic medication are used to prevent myocardial infarctions (MIs) and strokes [1,13]. Some PAD patients may require leg amputation to relieve the unbearable pain and life-threatening situation. To avoid amputation or other serious prognosis, angioplasty, stenting and peripheral artery bypass surgeries are used to restore blood flow to the legs in some patients [1,13,14]. However, PAD patients undergoing vascular surgeries had a significantly worse long-term
prognosis than CAD patients with similar procedures [15]. Furthermore, many PAD patients are not suitable candidates for interventional or revascularization surgeries. Therefore, therapeutic angiogenesis, i.e. promotion of angiogenesis and microcirculation using angiogenic factors, has been proposed as a new and potential treatment strategy for PAD patients in the last decade [16]. The administration of angiogenic factors, either as naked plasmid DNA or recombinant proteins, may promote neovascularization, augment the collateral circulation, and enhance blood perfusion to ischemic tissues [16,17]. Therapeutic angiogenesis for PAD made some progress, but also met some problems [16,18]. Several angiogenic factors, for example, vascular endothelial growth factor A (VEGF), fibroblast growth factors (FGFs), hepatocyte growth factor (HGF), and platelet-derived growth factor (PDGF), have been tested to treat critical limb ischemia in PAD patients or in animal models. These studies provided encouraging results, however, therapeutic angiogenesis for PAD is considered to be still at its infancy and adverse effects in some cases occurred, including vascular leakage, transient edema, and hypotension with administration of VEGF and FGFs [19,20].

Figure 1. Successful overexpression of AGGF1 mRNA and protein in skeletal muscle by gene transfer using a plasmid-based delivery system. A) Real time PCR analysis for expression of human AGGF1 mRNA derived from an AGGF1 expression plasmid injected into the gastrocnemius muscle in a mouse ischemic hindlimb model. The RT-PCR primers are specific to human AGGF1 and not able to amplify the endogenous mouse AGGF1 mRNA. Time points are in days after the injection of plasmid DNA. Injection of the empty vector DNA served as negative control. The data are shown as the amount of plasmid-derived human AGGF1 mRNA normalized to control GAPDH levels. To avoid the contamination of plasmid DNA, RNA samples were treated with DNase. In addition, RT-PCR analysis with RNA samples without reverse transcription did not yield any product. B) Expression of AGGF1 protein in gastrocnemius muscles by Western blot analysis at time points of 7, 14, 28 days after plasmid DNA was injected. The anti-AGGF1 antibody recognizes both human AGGF1 derived from the injected plasmid and endogenous mouse AGGF1 protein. C) The images from Western blot analysis in B) were scanned, quantified, and plotted. The intensity of AGGF1 signal was normalized to the signal of control β-actin. D) Immunohistochemical analysis of the sections of ischemic hindlimb muscle from mice injected with an empty vector (Control) and with an AGGF1 expression plasmid (AGGF1) with an anti-AGGF1 antibody seven days later by injection of plasmid DNA. *, P<0.05. doi:10.1371/journal.pone.0046998.g001
addition, the efficacy of therapeutic angiogenesis may be limited by the few number of angiogenic factors available for selection. Therefore, it is crucial that new angiogenic factors should be identified and tested for treating PAD.

AGGF1 is a new angiogenic factor identified by our group through genetic analysis of a congenital vascular disorder called Klippel-Trenaunay syndrome (KTS) [21,22]. AGGF1 protein contains several functional domains, including a coiled-coil motif at the N-terminus, an OCTamер REpeat (OCRE) domain, a Forkhead-associated (FHA) domain, and a G-patch domain at the C-terminus. The specific functions of these domains are unknown. We have demonstrated that AGGF1 promotes angiogenesis as potentially as VEGF in a chicken embryo angiogenesis assay [21]. Recently, we reported that GATA1 could regulate the expression of AGGF1 through two GATA1 binding sites in the promoter region of AGGF1 [23]. Knockdown of GATA1 expression reduced AGGF1 expression, which resulted in reduced endothelial capillary vessel formation in a matrigel vessel tube formation assay, and purified recombinant AGGF1 protein can rescue the defect when added in the media [23]. The angiogenic potential of AGGF1 prompted us to investigate whether therapeutic angiogenesis with administration of naked DNA for an AGGF1 expression construct is capable of increasing blood flow in a mouse hindlimb ischemia model.

Results

Successful Expression of AGGF1 by Administration of Naked Plasmid DNA into Gastrocnemius Muscle

Previous reports by others demonstrated that the efficiency of gene transfer by direct injection of DNA for an expression plasmid was determined by the amount of plasmid DNA and the injection volume [24]. An increase in injection volume and one site injection rather than separate injections at multiple sites resulted in higher transfection efficiencies. Therefore, we injected 0.2 mg of purified plasmid DNA in a 0.15 ml of volume for pcDNA3.1-AGGF1-FLAG (an expression construct for AGGF1) or control vector pcDNA3.1-FLAG into one site in the gastrocnemius muscle. At different time points, muscle tissue samples from ischemic and non-ischemic hindlimbs were harvested for real-time RT-PCR and Western blot analyses to measure the expression levels of AGGF1. As shown in Figure 1A, human AGGF1 mRNA in ischemic hindlimb tissues from mice injected with pcDNA3.1-AGGF1-FLAG increased dramatically compared with that from mice injected with control vector pcDNA3.1-FLAG one week after the injection of DNA (P<0.001). The expression of human AGGF1 remained high for two weeks after the injection, but decreased to a lower level four weeks after the injection (Figure 1A).

Similar results were obtained with Western blot analysis (Figure 1B). For Western blot analysis, the anti-AGGF1 antibody can also detect the endogenous mouse AGGF1 protein in the mice injected with control vector pcDNA3.1-FLAG. Moreover, increased human AGGF1 protein expression was found at the time points of seven days and fourteen days, but not at twenty-eight days in mice injected with pcDNA3.1-AGGF1-FLAG (Figure 1B). Consistent with these results, immunohistochemistry analysis also showed higher AGGF1 protein expression in tissues from mice injected with pcDNA3.1-AGGF1-FLAG than that from mice injected control vector pcDNA3.1-FLAG one week after the DNA injection (Figure 1D).

Together, these data suggest that direct injection of naked plasmid DNA for an AGGF1 expression construct into gastrocnemius muscles results in a successful high level of expression of both AGGF1 mRNA and protein.

Increased AGGF1 Expression Stimulated an Increase of Blood Flow in the Ischemic Hindlimb

We measured the change of blood flow in the hindlimb ischemia model using a high-resolution micro-ultrasound system. One day after surgery (ligation of arteries), the ratio of blood flow in the ischemic leg over that in the non-ischemic leg decreased sharply to 10% of the level before the surgery in mice injected with either pcDNA3.1-AGGF1-FLAG or control pcDNA3.1-FLAG (Figure 2A, 2C). In addition, the wave form of blood flow also changed dramatically and it was difficult to identify the pulse of blood flow after the surgery.

After the ischemia was confirmed by micro-ultrasound, 0.15 ml of PBS containing 0.2 mg of purified DNA was injected into the gastrocnemius muscle close to the ligation site of the ischemic hindlimb. In mice injected with pcDNA3.1-AGGF1-FLAG, the ratio of blood flow of ischemic/nonischemic hindlimbs increased significantly one week after DNA injection (Figure 2A, 2C) compared to control mice injected with pcDNA3.1-FLAG (P<0.05, n = 9). The increased blood flow in mice injected with pcDNA3.1-AGGF1-FLAG remained at the time point of two weeks. Four weeks after the injection of DNA, the blood flow was approximately 2.29 fold higher in mice injected with pcDNA3.1-AGGF1-FLAG than those injected with pcDNA3.1-FLAG (0.256±0.017 vs. 0.112±0.03; P = 0.001, n = 9).

We compared the effect of AGGF1 on blood flow to FGF-2, a potent angiogenic factor. The same amount of DNA for AGGF1 and FGF-2 expression plasmids (200 μg) was administered. Similar to AGGF1, FGF-2 also strongly stimulated blood flow in mouse hindlimb ischemic models. No difference was observed 7 and 14 days after gene transfer between the AGGF1 group and FGF-2 group. However, at day 28, AGGF1 performed significantly better than FGF-2 in stimulating blood flow in mouse hindlimb ischemic models (P = 0.054).

We then analyze the effect of different amounts of AGGF1 expression plasmid DNA on blood flow. As the amount of AGGF1 DNA increased from 10 μg to 500 μg, the blood flow increased (Figure 2B).

We also evaluated ischemic limb functions by scoring limb tissue necrosis and ambulatory impairment. Both scores decreased markedly in mice injected with pcDNA3.1-AGGF1-FLAG compared with those injected with pcDNA3.1-FLAG (tissue necrosis score in Figure 3A and 3B and ambulatory impairment score in Figure 3C and 3D). When compared to the same amount of FGF-2 expression plasmid DNA, AGGF1 was as equally competent as FGF-2 in inhibiting tissue necrosis and ambulatory impairment (Figure 3A and 3C). As the amount of AGGF1 DNA increased from 10 μg to 500 μg, both the tissue necrosis score and ambulatory impairment were reduced (Figure 3B and 3D).

Increased AGGF1 Expression Inhibited Necrosis in the Ischemic Hindlimb

H&E histological staining was carried out for ischemic hindlimb muscle sections for both pcDNA3.1-AGGF1-FLAG and control pcDNA3.1-FLAG groups of mice 7 days after DNA injection. In the control mice, ischemic hindlimb muscle sections showed centralization of nuclei and many necrosed muscle fibers (Figure 4), which indicated severe necrosis. However, in mice injected with pcDNA3.1-AGGF1-FLAG, centralized nuclei were less prominent, and the number of necrosed muscle fibers was highly reduced (Figure 4). Overall, ischemic gastrocnemius muscle sections from mice with overexpression of AGGF1 showed less gross tissue necrosis than that from mice without AGGF1 overexpression.

Potential of AGGF1 for Therapeutic Angiogenesis
Increased AGGF1 Expression Induced Angiogenesis in the Ischemic Hindlimb

The effect of overexpression of human AGGF1 on angiogenesis was examined in the ischemic hindlimbs by immunostaining of gastrocnemius muscle sections with an anti-CD31 antibody four weeks after DNA injection (Figure 5A). The density of CD31-positive vessels was significantly higher in mice injected with pcDNA3.1-AGGF1-FLAG than control pcDNA3.1-FLAG group of mice (0.934 ± 0.413/mm² vs. 0.538 ± 0.388/mm², P < 0.01) (Figure 5B). In addition, the number of CD31-positive vessels in fibers was also markedly increased in mice injected with pcDNA3.1-AGGF1-FLAG than the control group of mice with pcDNA3.1-FLAG injection (439.2 ± 250.1 vs. 172.5 ± 109.4, P < 0.05) (Figure 5C). These data suggest that overexpression of human AGGF1 induces angiogenesis in ischemic gastrocnemius muscles.

To exclude the possibility that increased angiogenesis in gastrocnemius muscle sections was related to VEGF, we carried out real time RT-PCR analysis for mouse VEGF using RNA samples isolated from gastrocnemius muscle tissues. No significant difference was found for the expression level of VEGF in tissues injected with AGGF1 expression plasmid DNA and with an empty vector DNA (Figure 6).
Discussion

The data in the present study indicate that gene transfer by administration of plasmid DNA for an AGGF1 expression construct promotes blood flow and improves hindlimb muscle microcirculation in a mouse model of PAD induced by ligation of both common iliac artery and femoral artery (Figure 2). Further studies showed that increased blood flow in the ischemic limb correlated with increased density of CD31-positive vessels and reduced tissue necrosis (Figures 3, 4, 5).

Critical limb ischemia is the most advanced stage of PAD, and is always associated with severe atherosclerosis. Atherosclerosis in peripheral arteries decreases blood flow and oxygen supply to the muscle tissue of limbs and toes, which may result in tissue necrosis due to hypoxia. This study is the first to investigate the potential of AGGF1 as a new strategy for therapeutic angiogenesis for critical limb ischemia. Our data indicate that AGGF1 can serve as a novel therapeutic agent for the treatment of critical limb ischemia as increased AGGF1 expression in skeletal muscles enhanced limb function, increased blood flow, and healed ischemic ulcers in a mouse hindlimb ischemia model.

For gene transfer involved in therapeutic angiogenesis, several delivery methods are used. Administration of purified recombinant proteins achieved some positive results, but short half-life of proteins and long-term toxicity with repeated injections may cause system toxicity. Infection with adenoviruses with the target gene is effective in achieving stable and long-term expression, but may induce adverse immune reactions. Davis et al [25] reported that injection of naked plasmid DNA appeared to be better for overexpressing a target gene in skeletal muscles than viral vectors because skeletal muscle cells were able to take plasmid DNA up. Thus, direct injection of plasmid DNA into skeletal muscle tissues has become an alternative to achieve a high level of gene transfer to avoid significant disadvantages with injection of a protein and an adenoviral vector. The data in the present study again showed that direct injection of DNA for an AGGF1 expression plasmid successfully overexpressed AGGF1 in the ischemic tissues (Figure 1). Two recent clinical trials, HGF-STAT and TALISMAN201 utilized a plasmid-
based angiogenic gene delivery system for HGF and FGF-1, respectively, and achieved some encouraging results (improved transcutaneous oxygen measurements TcPO2 in the HGF case and a reduced risk of major amputation and death in the FGF-1 case) [26,27]. More clinical trials are needed to replicate these findings. Similarly, future clinical studies for therapeutic angiogenesis using AGGF1 with a plasmid-based gene delivery system are needed to unequivocally establish the efficacy of AGGF1 treatment for PAD.

Tsurumi et al showed that administration of naked plasmid DNA encoding VEGF increased regional blood flow to the transfected thigh muscle and distal lower limb muscle by 1.5-fold in a rabbit ischemic hindlimb model [28]. Hiraoka et al. reported that in a rat model of hindlimb ischemia, injection of VEGF plasmid DNA increased blood flow by about 30% [24]. Taniyama et al. showed that injection of naked HGF plasmid DNA into skeletal muscle resulted in a 70% increase in blood flow in a rat model of hindlimb ischemia three weeks after the injection [29]. We demonstrated that injection of naked plasmid DNA for an AGGF1 expression construct resulted in a 2.29-fold increase in blood flow (Figure 2). Furthermore, our parallel comparison analysis found that AGGF1 was significantly better than FGF-2 in stimulating blood flow 28 days after gene transfer (P = 0.034), although no significant difference was found for day 7 and day 14 (Figure 2). Therefore, AGGF1 appears to be an excellent choice for therapeutic angiogenesis for critical limb ischemia.

Some side effects were uncovered in previous studies involving therapeutic angiogenesis for treating limb ischemia in PAD using VEGF and FGFs. The major adverse effects include increased vascular permeability (resulting in vascular leakage) and transient edema [19,20]. In contrast to VEGF, AGGF1 is required for maintaining the vascular integrity because adult heterozygous AGGF1+/− knockout mice showed increased vascular permeability in an assay using Evan’s blue dye [30]. During the AGGF1 treatment in a hindlimb ischemic mouse model for PAD, we did not observe any edema. However, future studies are needed to determine whether a larger dose of AGGF1 DNA injection may result in side effects of edema or other undesirable abnormalities in major organs such as the heart, livers, kidneys, lungs and other organs.

A long-standing question about the mode of action of AGGF1 during angiogenesis is whether it acts by an autocrine or paracrine mechanism [21,31]. Because the AGGF1 protein is
expressed and secreted by endothelial cells, we suggested that AGGF1 may act by an autocrine mode, however, we also stated that a paracrine mode of action was possible because AGGF1 was highly expressed in vascular smooth muscle cells [21]. In the present study we show that overexpression of AGGF1 in skeletal muscle cells can apparently promote strong angiogenesis (Figure 5). The data strongly suggest that AGGF1 is able to act by a paracrine mechanism. The molecular mechanism by which AGGF1 promotes angiogenesis remains to be further explored. Decreased expression of AGGF1 resulted in massive apoptosis of endothelial cells, whereas recombinant AGGF1 can rescue this abnormality when coated onto wells of culture plates [23]. Similar results were obtained for endothelial cell migration [23]. Thus, AGGF1 promotes angiogenesis by acting as a surviving factor for endothelial cells or by promoting endothelial cell migration. We have shown that AGGF1 interacts with TWEAK [21], which promotes angiogenesis as potently as VEGF and FGF-2 [32]. TWEAK acts by binding to its receptor fibroblast-growth factor inducible 14 (Fn14). Thus, AGGF1 may promote angiogenesis by interacting with TWEAK. Alternatively, AGGF1 may have its own receptor during angiogenesis. Future studies can focus on identifying the receptor for AGGF1 and the detailed molecular signaling mechanism involved in AGGF1-mediated angiogenesis.

In conclusion, the data in this study suggest that gene transfer using AGGF1 naked plasmid DNA significantly increases blood flow by promoting angiogenesis and inhibiting tissue necrosis in a mouse model of critical hindlimb ischemia for PAD. Therapeutic angiogenesis with AGGF1 may be beneficial to patients with not only PAD, but also other ischemic conditions such as ischemic heart disease, MIs, and strokes.

Figure 5. Overexpression of human AGGF1 stimulated angiogenesis in a mouse hindlimb ischemia model. A) Representative images of sections of ischemic hindlimb muscles immunostained with an anti-CD31 antibody 7, 14, or 28 days after injection of AGGF1 plasmid DNA or empty vector DNA (control). B) Quantification of density of CD-31-positive vessels per mm² in ischemic muscles 28 days after injection of DNA. C) The number of CD-31-positive vessels per muscular fiber 28 days after injection of DNA. *, P<0.05.
doi:10.1371/journal.pone.0046998.g005
Materials and Methods

Animals and a Hindlimb Ischemic Model

Male C57BL/6 mice were obtained from the Animal Facility at Wuhan University Zhong Nan Hospital. Animal care and experimental procedures were approved by the Ethics Committee of College of Life Science and Technology, Huazhong University of Science and Technology.

Gene Transfer

The cDNA for human AGGF1 was obtained using RT-PCR analysis with total RNA samples from HeLa cells (ATCC). The PCR product was digested with BamHI and NotI and cloned into the PCR primers, and cloned into vector pcDNA3.1-FLAG, resulting in a mammalian expression construct for AGGF1 (pcDNA3.1-AGGF1-FLAG). The entire insert in the AGGF1 expression construct was sequenced and verified. The expression plasmid for FGF-2 was developed as for AGGF1.

One day after the ischemia surgery, 0.15 ml of 1.33 μg/μl DNA (200 μg) for either pcDNA3.1-AGGF1-FLAG or pcDNA3.1-FLAG was injected into the gastrocnemius muscle close to the ligation site of the right ischemic hindlimb [24,35,36]. Mice were sacrificed at various time points after the injection and characterized.

Blood Flow Analysis

The blood flow in both legs was measured using a Vevo 2100 High-Resolution Microultrasound System (Visualsonics Inc, Toronto, Canada) immediately before the ischemia surgery and at different time points of postoperative days 1, 8, 15, 22 and 29. The Microultrasound System allows for repeated, noninvasive and quantitative measurements of the blood flow of the certain sites of the artery. The surgical outcome of limb ischemia at the right leg, but not the left leg, was confirmed by the Microultrasound System. The mice were anesthetized with 1% isoflurane, placed on a heat pad, and kept at 37°C to minimize data variations caused by fluctuating body temperatures. Excess hairs were removed by depilatory cream from the urite to the limb before analysis [37].

Figure 6. Overexpression of human AGGF1 in a mouse hindlimb ischemia model does not affect the expression level of VEGF.

Potential of AGGF1 for Therapeutic Angiogenesis

Physical Examinations of Tissue Necrosis and Ambulatory Impairment

Tissue necrosis was scored as described [38]. “0” was for no necrosis, “1” for necrosis of one toe, “2” for necrosis of two or more toes “3” for necrosis of the foot, “4” for necrosis of the leg, and “5” for autoamputation of the entire leg.

The severity of ambulatory impairment was assessed by using the following scale as described [38,39]. “0” was for normal response (plantar/toe flexion in response to tail traction), “1” for plantar but not toe flexion, “2” for no plantar or toe flexion, “3” for dragging of foot, and “4” for spontaneous movement of non-ischemic hindlimb. Physical examinations of both tissue necrosis and ambulatory impairment were performed by an observer who was blinded to treatments.

Quantitative Real-time PCR Analysis

Total RNA samples were extracted from gastrocnemius muscles using TRIzol (Invitrogen), precipitated with isopropanol, and treated with RNase-Free DNase (Promega) to eliminate DNA contamination. The synthesis of the first-strand cDNA was performed using M-MLV Reverse Transcriptase (Promega). Real-time RT-PCR analysis was performed using the FastStart Universal SYBR Green Master (Roch) and a 7900 HT Fast Real-Time PCR System (ABI).

The sequences for the RT-PCR primers were as follows: 5'-GTTGTTGGCAACA-3' (sense) and 5'-CCTCATTACT-TAGTGTTGGCAACA-3' (antisense) for AGGF1, 5'-AGGTCGGTGTGAACGGATTTG-3' (sense) and 5'-TGGACCATGTAGTTGAGGTCA-3' (antisense) for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 5'-GACCATGTAGTTGAGGTCA-3' (sense) and 5'-CGGACACAGGAGGAGGAC-3' (antisense) for mouse VEGFA. GAPDH served as an internal standard. The data were analyzed using 2^-∆∆Ct relative expression quantity as described [40].

Western Blotting Analysis

Ischemic and non-ischemic calf muscles were weighed, homogenized, and centrifuged in RIPA buffer containing protease and phosphatase inhibitor cocktails (Roche Diagnostics). A 20 μg of total protein extracts was separated on 10% SDS-PAGE gels, and transferred to nitrocellulose membranes (Millipore). The membranes were blocked with 4% milk powder, washed with TBST, and incubated with a polyclonal anti-AGGF1 antibody or a control anti-β-actin antibody (Proteintech) overnight at 4°C. The membranes were washed with TBST and incubated with peroxidase-conjugated anti-rabbit IgG (Sigma) as a secondary antibody. The membranes were washed with TBST, and developed using Supersignal Chemiluminescence Substrate system (Pierce). The protein signal was imaged and analyzed using ChemiDoc XRS (BioRad).
Histology and Immunohistochemistry Analysis

Immunohistochemistry was performed as described [41]. Muscle samples were fixed in 4% paraformaldehyde, paraffin embedded, and sectioned (8 μm). The sections were deparaffinized using xylene (dimethyl benzene), and heated in citrate buffer (pH 6.0) or 1 mM/L EDTA (pH 8.0) to retrieve antigen. Slides were then blocked with 3% H2O2 and then 10% goat serum, and incubated with the primary anti-AGGF1 antibody or an anti-CD31 antibody for 1 hour at room temperature for overnight at 4°C. The sections were then washed with PBS and incubated with a secondary, biotinylated anti-rabbit IgG for 15 minutes, followed by washing in PBS, and incubation with SABC kit (Boster). The signals were developed with a DAB chromogen kit (Dako) and counterstained with hematoxylin. Replacement of the primary antibody with PBS served as a negative control. All measurements were performed in a blinded manner. Six sections were randomly studied for each mouse and viewed at 40X viewing fields to measure average positive immunoreactivity. To avoid confounding caused from trauma effects of the needle injection, the analysis was made outside of the needle injection area.

Statistical Analysis

All data were expressed as mean ± SEM. Statistical analysis was carried out using a Student’s t-test for comparison between two groups. A P value of <0.05 was considered significant.

Acknowledgments

We thank Dr. Fan Wang and Shaofang Nie for discussion on this work.

Author Contributions

Conceived and designed the experiments: QW XT. Performed the experiments: QL YHY YFY SL YH YL BZ YX LL NW LW JZ XG WM. Analyzed the data: QL YHY YFY SL YH SL. Wrote the paper: QW QW. Supervising the study: CX GQ.

References

1. Hirsch AT, Haskal ZJ, Berkey NR, Bakal CW, Creager MA, et al. (2006) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol 47: 1239–1312.

2. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, et al. (1994) Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 94: 3026–3049.

3. Rooble T, Hirsch AT, Mura S, Sidaway A, Beckmann J, et al. (2011) 2011 ACCF/ AHA focused update of the guideline for the management of patients with peripheral arterial disease (Updaiting the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 59: 2040–2054.

4. Hwang YR (2001) Medical treatment of peripheral arterial disease and classification. N Engl J Med 344(21): 1608–1613.

5. Selvin E, Erlinger TP (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110: 738–743.

6. Lange S, Diehm C, Harzing H, Habelt R, Allenberg JR, et al. (2003) High prevalence of peripheral arterial disease but low antplatelet treatment rates in elderly primary care patients with diabetes. Diabetes Care 26: 3357–3359.

7. Long GC, Lee AJ, Low PG, Whitman M, Dunbar J, et al. (1996) Incidence, natural history, and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25: 1172–1181.

8. Puri P, Mather MH, Langer RD, Franko A, Feigelson HS, Klauer MR, et al. (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381–386.

9. Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, et al. (2003) Lower extremity peripheral arterial insufficiency in hospitalized patients with coronary artery disease. Vase Med 8: 253–256.

10. Welten GM, Schouten O, Chonchol M, Hoeks SE, Bas J, et al. (2009) Prognosis of patients with peripheral arterial disease. J Cardiovasc Surg 50: 109–121.

11. Vogt MT, Wolfson SK, Kuller LH (1992) Lower extremity arterial disease and the aging process: a review. J Clin Epidemiol 45: 529–542.

12. Brevetti G, Giugliano G, Brevetti L, Hant WR (2010) Inflammation in peripheral arterial disease. Circulation 122: 1062–1075.

13. Olin JW, Sealeva BA (2010) Peripheral arterial disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc 85(7): 678–692.

14. Costantini V, Lenti M (2002) Treatment of acute occlusion of peripheral arteries. Thermod 106(6): V285–294.

15. Matyas L, Schulte KL, Dormandy JA, Norgren L, Sowade O, et al. (2005) Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth-factor-4. Hum Gene Ther 16(16): 1202–1211.

16. Mughal NA, Russell DA, Ponnambalam S, Honer-Vanniasinkam S (2012) Gene therapy in the treatment of peripheral arterial disease. Br J Surg 99: 6–15.
37. Fitzgerald SM, Bashari H, Cox JA, Parkington HC, Evans RG (2007) Contributions of endothelium-derived relaxing factors to control of hindlimb blood flow in the mouse in vivo. Am J Physiol Heart Circ Physiol 293: H1072–H1082.

38. Qi X, Okamoto Y, Murakawa T, Wang F, Oyama O, et al. (2010) Sustained delivery of sphingosine-1-phosphate using poly(lactic-co-glycolic acid)-based microparticles stimulates Akt/ERK-eNOS mediated angiogenesis and vascular maturation restoring blood flow in ischemic limbs of mice. Eur J Pharmacol 634(1–3): 121–131.

39. Bosch-Marc M, Okuyama H, Wesley JR, Sarkar K, Kimura H, et al. (2007) Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 101: 1310–1318.

40. Wang F, Xu CQ, He Q, Cai JP, Li XC, et al. (2011) Genome-wide association identifies a susceptibility locus for coronary artery disease in the Chinese Han population. Nat Genet 43(4): 345–349.

41. Wu L, Yong SL, Fan C, Ni Y, Yoo S, et al. (2008) Identification of a new cofactor, MOG1, required for the full function of cardiac sodium channel Nav1.5. J Biol Chem 283: 6968–6978.